- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
- CEL-SCI Corporation Issues Letter to Shareholders
More ▼
Key statistics
On Friday, CEL-SCI Corp (CVM:ASQ) closed at 1.27, 22.12% above the 52 week low of 1.04 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.30 |
---|---|
High | 1.34 |
Low | 1.25 |
Bid | 1.26 |
Offer | 1.37 |
Previous close | 1.30 |
Average volume | 334.55k |
---|---|
Shares outstanding | 54.16m |
Free float | 52.38m |
P/E (TTM) | -- |
Market cap | 70.41m USD |
EPS (TTM) | -0.6304 USD |
Data delayed at least 15 minutes, as of May 24 2024.
More ▼